1 Homology Language Brian R. Stanton Quality Assurance Specialist Technology Center 1600 U.S. Patent and Trademark Office (703) 308-2801

Slides:



Advertisements
Similar presentations
Unity of Invention Biotechnology Practice Julie Burke USPTO TC1600 Special Program Examiner.
Advertisements

Michael P. Woodward Supervisory Patent Examiner, Art Unit 1631 (703) Bioinformatics & §101
Enablement Issues in the Examination of Antibodies
Written Description: Antibodies Bennett Celsa TC 1600 QAS
Filing for a United States Patent “Helpful Hints” U.S. Patent and Trademark Office.
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
1 Types of Vaccines and Patentability Considerations Christina Chan Supervisory Primary Examiner Art Unit 1644 Phone:
Utility and Written Description Steve Kunin Deputy Commissioner for Patent Examination Policy Esther Kepplinger Deputy Commissioner for Patent Operations.
Common Claim Breadth Issues in Plant- Related Applications Anne Marie Grünberg Supervisory Patent Examiner Art Units 1661 and 1638.
Benefit to Society Good Science. Human genes claimed in granted U.S. patents Jensen and Murray, Science 310: (14 Oct. 2005) “Specifically, this.
1 Restriction Examples Biotechnology Customer Partnership Meeting December 2006 Bruce Campell, SPE 1648 / (571)
1. 2 Biotechnology Inventions: Genes & Life Forms and the Impact of Patenting on Upstream Science Nancy J. Linck, Ph.D., J.D. Deputy General Counsel Intellectual.
Proteomics and “Orphan” Receptors Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
“REACH-THROUGH CLAIMS”
1 Biotechnology Partnership Meeting April 17, 2001 James Martinell Senior Level Examiner Technology Center 1600.
Restriction Practice for Nucleic Acid Molecules Julie Burke QAS/PM
1 Single Nucleotide Polymorphisms (SNP) Gary Jones SPE, Technology Center 1600 (703)
Animals and Transgenesis Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Transgenic Animals — How they are made Examination of Transgenic.
Assessing Compliance with the Utility Requirement of 35 U.S.C. § 101 based on the Sequence Homology Dave Nguyen, tQAS TC
Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Examining Issues When.
Expect value Expect value (E-value) Expected number of hits, of equivalent or better score, found by random chance in a database of the size.
Issues in Patenting Proteins Jon P Weber, SPE 1657.
1 Automated Searching of Polynucleotide Sequences Michael P. Woodward Supervisory Patent Examiner - Art Unit
Examination Issues: Immunology Yvonne (Bonnie) Eyler Quality Assurance Specialist Technology Center 1600 USPTO (571)
1 Unity of Invention: Biotech Examples TC1600 Special Program Examiner Julie Burke (571)
RESTRICTING BETWEEN PRODUCT and PROCESS INVENTIONS Bruce Campell Supervisory Patent Examiner Art Unit
Stem Cells Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Stem Cells — Origin Examination of Stem Cell Claims — Statutes — Sample Claims.
Patenting Antibodies in Europe
Julie Burke TC1600 QAS/PM New Matter, Incorporation By Reference, Restriction and Claim Language for Nucleic Acid Molecules.
Examination of Protein Crystallography Applications Kathleen Kerr Bragdon, Ph.D. Supervisory Patent Examiner Art Unit 1656.
Korean Patent System and Recent Changes. Practices in Chemistry. Bong Sig SONG Korean Patent Attorney Y. S. CHANG & ASSOCIATES February 9 th 2008.
1 Kathleen Kerr Bragdon Quality Assurance Specialist Technology Center 1600 Kathleen Kerr Bragdon Quality Assurance Specialist Technology Center 1600 Patents.
1 “In the Examination Process” CLAIM INTERPRETATION.
Impact of Myriad Decisions on Patent Eligibility of Biotechnology Inventions in Australia and the US.
© 2011 Barnes & Thornburg LLP. All Rights Reserved. This page, and all information on it, is the property of Barnes & Thornburg LLP which may not be reproduced,
Patenting Interfering RNA
Patenting Biotechnology in Japan and recent hot issues AIPLA Mid-Winter Meeting January 25, 2012 Ayako Kobayashi TMI Associates.
U.S. Patent and Trademark Office Technology Center 1600 Michael P. Woodward Unity of Invention: Biotech Examples.
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
PfDGAT1-1 PfDGAT1-2 AtDGAT1 RcDGAT1 PfDGAT1-1 PfDGAT1-2 AtDGAT1 RcDGAT1 PfDGAT1-1 PfDGAT1-2 AtDGAT1 RcDGAT1 PfDGAT1-1 PfDGAT1-2 AtDGAT1 RcDGAT1 PfDGAT1-1.
Patentability of Reach-Through Claims Brian R. Stanton Practice Specialist Technology Center 1600 (703)
Sequence Search and Analysis SPE 1653 (703)
Patentability Considerations in the 3-D Structure Arts Patentability Considerations in the 3-D Structure Arts Michael P. Woodward Supervisory Patent Examiner.
Trilateral Project WM4 Report on comparative study on Examination Practice Relating to Single Nucleotide Polymorphisms (SNPs) and Haplotypes. Linda S.
[ w w w. d u a n e m o r r i s. c o m ] ● ©2008 Duane Morris LLP. All Rights Reserved. Duane Morris is a registered service mark of Duane Morris LLP. ●
1 Demystifying the Examination of Stem Cell-Related Inventions Remy Yucel, Ph.D. Supervisory Patent Examiner Technology Center 1600 United States Patent.
Examining Claims for Compliance with 35 U.S.C. 112(a): Part II – Enablement Focus on Electrical/Mechanical and Computer/Software-related Claims August.
Patent Protection of Biotechnological Inventions in China Gesheng Huang Partner Zhongzi Law Office AIPLA Spring Meeting, May 12-14, 2011, San Francisco,
Restriction Practice for Combinations and Subcombinations
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
Patenting Interfering RNA John LeGuyader – SPE Art Unit 1635 (571)
1 1 AIPLA Firm Logo American Intellectual Property Law Association More Fun with §101 – A Prosecution Perspective for Biotechnology Derived Innovation.
How to Claim your Biotech- Based Invention Deborah Reynolds Detailee, TCPS
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
1 Searching in Applications Containing Bio-Sequences Ram R. Shukla Supervisory Patent Examiner Art Unit
Myriad The Future of DNA Claims Mercedes Meyer, Ph.D., JD AIPLA 1.
1 Utility Guidelines, Homology Claims and Anti-Sense Molecule Claims Drew Hissong, Ph.D. dhissong*sughrue.com Sughrue Mion, PLLC
Variation among organisms
Patenting Biotechnology in Japan and recent hot issues
Patentability Issues and Mechanism Claims
Figure 1. Annual growth rates of the number of records in each Entrez database as of 1 September 2018. Identical Protein Groups is not included since this.
Review of Ch. 11 DNA.
MACROMOLECULES A very large molecule consisting of many smaller structural units linked together.
The future of protein secondary structure prediction accuracy
Nucleotide sequences encoding part of the VP1 capsid protein of FMDVs derived from infected cattle in phase I and phase II of the study. Nucleotide sequences.
Automated Searching of Polynucleotide Sequences
Structural evidence: Embryonic similarities Vestigial organs
Examination Practice in Applications Presenting “Reach-Through Claims”
Examination Issues: Immunology
Presentation transcript:

1 Homology Language Brian R. Stanton Quality Assurance Specialist Technology Center 1600 U.S. Patent and Trademark Office (703) Biotechnology/Chemistry/Pharmaceutical Customer Partnership U.S. Patent and Trademark Office Arlington, Va July 29, 2003

2 Language % identical Homology, identity, similarity Hybridization

3 Sample Claims An isolated and purified nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 1. An isolated and purified nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 1 wherein said nucleic acid encodes a protein having activity X.

4 Sample Claims An isolated and purified nucleic acid comprising a nucleotide sequence that is 90% identical to SEQ ID NO: 1. An isolated and purified nucleic acid comprising a nucleotide sequence that is 90% identical to SEQ ID NO: 1, wherein said nucleic acid encodes a protein having activity X. The specification provides sufficient support that isolated protein has a specific, substantial, and credible use related to activity X.

5 Written Description An isolated and purified nucleic acid comprising a nucleotide sequence that is 90% identical to SEQ ID NO: 1. An isolated and purified nucleic acid comprising a nucleotide sequence that is 90% identical to SEQ ID NO: 1, wherein said nucleic acid encodes a protein having activity X.

6 Functional language If the specification provides sufficient support that the isolated protein has a specific, substantial, and credible use related to activity X, limiting the claims to proteins having activity X may help resolve a scope of enablement issue.

7 Enablement How to make? How to find?

8 Scope of enablement (some considerations) Consensus sequences State of the Art Specification Support Alignments? Critical Residues What to change and what not to change Variations What substitutions, deletions, insertions may be made? Where can changes be made?

9 Enablement: Claim language (some considerations) Consensus sequence in claim? Critical residues in claim? e.g. An isolated and purified nucleic acid comprising a nucleotide sequences that is 90% identical to SEQ ID NO: 1, wherein said nucleic acid encodes a protein having activity X, and further wherein said nucleic acid includes SEQ ID NO: 2. SEQ ID NO: 2 is the nucleotide sequence that encodes the catalytic domain (SEQ ID NO: 3) of a protein having activity X. SEQ ID NO: 3 is sufficient to endow a protein with catalytic activity X.

10 What % homology is appropriate? Distinguish over prior art Technology based Do alignments yield information that suggests an appropriate amount of variation?

11 Consensus Sequence Example A G C T T C C G G C T T A T A A A C G T A C T A T C C A G T A T A A A T A C T T Consensus A x x x T C C x G x x T A x A x A C x T 11/20 = 55% homology between the two molecules. Do they both have the desired function? Are there teachings re: the permitted changes for the degenerate positions? What is the homology at the amino acid level? Are there teachings re: the permitted changes at the amino acid level?

12 Enablement (cont.) Assay How to find? How to screen for operative embodiments? Wands analysis